Comparative Pharmacology
Head-to-head clinical analysis: CORVERT versus DURAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORVERT versus DURAQUIN.
CORVERT vs DURAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibutilide, a class III antiarrhythmic agent, prolongs atrial and ventricular refractoriness by blocking delayed rectifier potassium current (IKr) and activating slow inward sodium current (INa-S).
Quinidine is a class Ia antiarrhythmic agent that blocks sodium channels, slowing phase 0 depolarization, prolongs the action potential duration, and increases the effective refractory period. It also exhibits anticholinergic and negative inotropic effects.
1 mg intravenously over 10 minutes; repeat once after 10 minutes if conversion to sinus rhythm not achieved. Maximum total dose: 2 mg.
Quinidine sulfate 324 mg orally every 8-12 hours, adjusted based on serum quinidine levels.
None Documented
None Documented
Terminal elimination half-life is approximately 6 hours (range 2–12 hours) in patients with normal renal function. Prolonged in renal impairment (up to 16 hours in severe impairment).
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function. Clinically, dose adjustment may be needed in renal impairment (half-life prolonged to up 18 hours) or hepatic impairment.
Renal (approximately 82% of total clearance), with about 18% biliary/fecal elimination. Mostly unchanged drug and metabolites.
Primarily hepatic metabolism (90-95%) to inactive metabolites, with renal excretion of unchanged drug <5% and metabolites. Fecal elimination accounts for <5% due to biliary excretion of metabolites.
Category C
Category C
Antiarrhythmic
Antiarrhythmic